Elevated levels of serum TK1 in Hodgkin Lymphoma patients

AroCell announces today that a new publication titled “Serum concentration of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma” is now available in the scientific journal Upsala Journal of Medical Science.

The article is written by Johan Mattison Ulfsted, Per Venge, Staffan Eriksson et.al. and is based on a study where Thymidine kinase 1 (TK1) serum concentration levels were measured in 58 patients with Hodgkin’s Lymphoma at diagnosis, relapse, or treatment, and was compared with healthy samples. The TK1 concentration in serum samples was measured using the AroCell TK 210 ELISA assay.

The study showed that patients with Hodgkin’s lymphoma have significantly higher concentrations of TK1 with increasing concentrations with increasing disease stages. The study also showed TK1 to increase during chemotherapy in the majority of patients.

“We are happy with these exciting results that will broaden the application of AroCell TK 210 ELISA and measurement of TK1 concentrations in other oncology areas. Illustrating that TK1 can be a useful biomarker in the evaluation of patients with advanced Hodgkin Lymphoma” says Anders Hultman, AroCells CEO.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.